2024-05-31 15:23:59 ET
Summary
- Bruker Corporation is a life science research and diagnostics firm which has seen a solid 2023.
- The company pursued an aggressive acquisition strategy this year, raising questions about the impact on sales, earnings, and debt.
- With the pro forma impact of these deals largely unknown, management not willing to provide much clarity and shares being solid at lower levels, investors act rightfully cautious.
Late in April, I took a look at shares of Bruker Corporation ( BRKR ) after the company pursued an aggressive acquisition strategy, which included some smaller deals and two larger acquisitions, as the pace of dealmaking raised some questions....
Read the full article on Seeking Alpha
For further details see:
Bruker: A Confusing Acquisition Spree